Aurobindo Pharma Subsidiary Faces Five Observations from U.S. FDA
AI Summary1 min read
TL;DR
Aurobindo Pharma's APL Healthcare unit in Andhra Pradesh received five procedural observations from the US FDA. The company will respond on time and remains committed to global quality standards, following similar issues at another subsidiary.
Tags
Aurobindo PharmaUS FDAobservationspharmaceutical manufacturingquality standards
Aurobindo Pharma subsidiary APL Healthcare's unit in Andhra Pradesh received five observations from the US FDA. The observations are procedural in nature and the company will respond within the stipulated timelines. The company is committed to maintaining the highest quality manufacturing standards at all its facilities worldwide. This comes after the FDA issued three observations to another subsidiary's API manufacturing facility in Hyderabad.
